Trial Profile
Randomized Phase 3 Study Evaluating the Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 15 Nov 2022
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Gemcitabine; Romidepsin
- Indications Peripheral T-cell lymphoma
- Focus Therapeutic Use
- Sponsors Celgene Corporation
- 11 Nov 2022 Planned End Date changed from 31 Jan 2023 to 29 Feb 2024.
- 19 Oct 2022 Planned End Date changed from 14 Jan 2021 to 31 Jan 2023.
- 07 Aug 2020 Planned End Date changed from 31 Dec 2021 to 14 Jan 2021.